Overview

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
Phase:
Phase 2
Details
Lead Sponsor:
Pearl Therapeutics, Inc.
Treatments:
Bromides
Tiotropium Bromide